The company has submitted biologics license application (BLA) with to the FDA for its long-acting site-specifically PEGylated recombinant human factor VIII to treat Hemophilia A. BAY94-9027 has been
Claimed to be the first of its kind approval, the FDA has approved Kymriah to treat patients up to 25 years of age with B-cell precursor ALL, which
The ADC programs covered in the deal are IMGN779 and IMGN632 with an additional program also expected to be designated during the agreement term. While IMGN779 is a
Merck, along with the researchers in the clinical trial service unit at the University of Oxford, reported that anacetrapib has reduced the risk of major coronary events by
The CSL subsidiary will pay an upfront payment of $91m for the acquisition. CSL Behring will get to add a pre-clinical asset in CAL-H, an HSC gene therapy
As per terms of the agreement, Gilead will pay $180.00 per Kite share in cash, representing a 29% premium to its closing price on 25 August. Based in
As per terms of the transaction, Regenxbio will pay $3.41 per Dimension share, which could be valued at around $86m. The acquisition will add Regenxbio with two product
The bispecific monoclonal antibody is intended to be used as a once-weekly subcutaneous treatment for the disease to cover adults, adolescents and children. According to Roche, emicizumab binds
Both the compounds were discovered through the research collaboration between Zealand and Boehringer Ingelheim. According to Zealand, the glucagon/GLP-1 agonist activates two key gut hormone receptors GLP-1 and
Ibrance is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which triggers cellular progression. Patina is a randomized, open-label and phase 3 clinical trial, which will assess
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.